Skip to main content

Expert Intelligence

Category: AI in Healthcare

An AI-driven decision automation platform designed to eliminate the human-review bottleneck in regulated laboratories by automating the analysis of complex analytical data. Expert Intelligence was founded in 2023. The company is led by Lalin Theverapperuma. Based in Santa Clara, USA. Team size: 11-50. Total funding raised: $5.8M. Latest round: Seed. Key investors include ["Sierra Ventures","TSVC","Acorn Pacific Ventures"].

Founded
2023
Headquarters
Santa Clara, USA
Team size
11-50
Total funding
$5.8M

Value proposition

Accelerates time-to-insight and reduces operational costs by providing audit-ready, high-precision AI automation that replicates expert-level judgment in data interpretation.

Products and solutions

["Laboratory Signal Modeling (LSM) Platform","AI-driven Mass Spectrometry Analysis Suite","Automated Proteomics Workflow Engine","Regulatory-compliant Decision Automation Interface"]

Unique value

Unlike general-purpose AI, their platform uses 'Laboratory Signal Modeling' (LSM) specifically designed to handle the high-noise, high-stakes data of regulated labs with audit-ready transparency.

Target customer

Pharmaceutical companies, clinical diagnostic labs, Contract Research Organizations (CROs), and biotechnology firms.

Industries served

["Life Sciences","Pharmaceuticals","Healthcare Diagnostics","Biotechnology"]

Technology advantage

Leverages deep expertise in Digital Signal Processing (DSP) and Machine Learning from the founding team's background at Apple and Meta to process raw analytical signals with higher fidelity than standard software.

How they differentiate

Expert Intelligence differentiates through 'Laboratory Signal Modeling' (LSM), applying high-fidelity digital signal processing (DSP) techniques—honed by the founders at Apple and Meta—to raw analytical data. Unlike general LIMS or data integration platforms, it focuses on automating the expert-level interpretation of complex signals (like mass spectrometry) with audit-ready precision.

Main competitors

["TetraScience","Scitara","Waters Corporation (Empower Software)","Thermo Fisher Scientific (Ardia Platform)"]

Key partnerships

["Sierra Ventures","TSVC","Acorn Pacific Ventures","Strategic pilot partners in the pharmaceutical and mass spectrometry sectors"]

Notable customers

["Confidential Tier-1 Pharmaceutical Companies","Contract Research Organizations (CROs)","Clinical Diagnostic Labs"]

Major milestones

["Successfully raised $5.8M Seed funding led by Sierra Ventures (Oct 2024)","Launched the proprietary Laboratory Signal Modeling (LSM) platform","Recruited key leadership from Apple, Meta, and Agilent Technologies","Established strategic partnerships within the mass spectrometry and proteomics sectors"]

Growth metrics

Early-stage startup; team size estimated between 11-50 employees; currently in the pilot and early deployment phase with major pharmaceutical partners.

Market positioning

Specialized AI deep-tech provider for regulated life sciences and analytical chemistry laboratories.

Geographic focus

North America (Headquartered in Santa Clara, CA) with a focus on global pharmaceutical and biotechnology hubs.

Patents and IP

Proprietary Laboratory Signal Modeling (LSM) algorithms (Specific patent filings not publicly disclosed in detail as of latest update).

About Lalin Theverapperuma

Lalin Theverapperuma is a distinguished AI leader and Ph.D. engineer with over 20 years of experience. He previously served as a key architect at Apple, leading ML and DSP for iPhone 4 through iPhone 8 and AirPods. He was the Hybrid Machine Learning Lead at Meta for the Metaverse and co-founded SafeAI, a leader in autonomous heavy equipment. His deep technical background includes roles at Vicarious AI, Intel, and Bosch.

Official website: